Compare Novavax Inc (NVAX) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Shopify Inc. — how do they compare? Novavax Inc trades at $12.7 (market cap $1.82B), while Shopify Inc. trades at $169 (market cap $211.73B). The key difference: Shopify Inc. is far larger — about 116.3× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Shopify Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Shopify Inc. for 78 Days on average.
| NVAX | SHOP | |
|---|---|---|
Market Cap | $1.82B | $211.73B |
Volume | 6,198,505 | 7,146,651 |
Sector | Health | Technology |
52-Week High | $12.56 | $179.01 |
52-Week Low | $6.22 | $95.40 |
Typical Hold Time | 59 Days | 78 Days |
Enterprise Value | $1.39B | $206.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
SHOP trades at $168.69, up 1.66% today, with strong technical momentum as moving averages signal bullish sentiment. The company shows robust revenue growth from $5.6B in 2022 to $11.56B in 2025, though recent Q4 2025 EPS missed expectations. Analyst consensus remains bullish with 67% buy ratings and a $168.63 price target, while Shopify's AI innovations like Canvas and open AI agent access position it competitively against Amazon.
Outlook: Shopify's expanding merchant solutions and AI-driven commerce tools support growth, but high valuation multiples (P/E 111.19) and overbought RSI levels pose near-term risks. Investors should weigh strong fundamentals against premium pricing and competitive pressures in the e-commerce sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
